Non‐Membrane Active Peptide Resensitizes MRSA to β ‐Lactam Antibiotics and Inhibits S. aureus Virulence
Advanced Science · 2025
DOI: 10.1002/advs.202416260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jingru Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzho…. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Anti-Bacterial Agents, beta-Lactams, Staphylococcal Infections. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Program of Jiangsu Province (Modern Agriculture), Jiangsu Agricultural Science and Technology Innovation Fund, National Natural Science Foundation of China.
Abstract (Originalsprache)
Methicillin‐resistant Staphylococcus aureus (MRSA) is a serious global health threat due to its high morbidity and mortality rates, creating a dire need for novel therapeutic strategies. Antimicrobial peptides (AMPs), with broad‐spectrum activity and low propensity for resistance development, show promise as effective antibiotic adjuvants to reverse multidrug‐resistance in bacteria. Herein, it is uncovered that a potent and non‐toxic AMP termed GN1 substantially resensitizes MRSA to multiple β ‐lactam antibiotics at low concentrations. Mechanistic studies indicate that GN1 functions by suppressing both the production and enzymatic activity of MRSA‐associated resistance determinants, including penicillin‐binding protein 2a (PBP2a) and β ‐lactamase. Additionally, GN1 exhibits a robust anti‐virulence profile by inhibiting MRSA biofilm formation and staphyloxanthin production. Furthermore, GN1 induces bacterial metabolic perturbation, resulting in glutamate accumulation and oxidative damage. Importantly, the combination of GN1 with β ‐lactam antibiotics effectively mitigates MRSA‐induced infections in the animal infection models. Collectively, these findings suggest that GN1 represents a potent β ‐lactam adjuvant and anti‐virulence agent, offering a safe and versatile solution to combat MRSA infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou, 225009, China.
- Joint International Research Laboratory of Agriculture and Agri-Product Safety, the Ministry of Education of China, Yangzhou University, Yangzhou, 225009, China.
- Institute of Comparative Medicine, Yangzhou University, Yangzhou, 225009, China.
ORCID-Profile: Yuan Liu
Förderung
- Key R&D Program of Jiangsu Province (Modern Agriculture)
- Jiangsu Agricultural Science and Technology Innovation Fund
- National Natural Science Foundation of China
Zitieren
APA
Shi, J., Chen, C., Kong, P., Yu, F., Lv, Q., Wang, Z., & Liu, Y. (2025). Non‐Membrane Active Peptide Resensitizes MRSA to β ‐Lactam Antibiotics and Inhibits S. aureus Virulence. Advanced Science. https://doi.org/10.1002/advs.202416260
Vancouver
Shi J, Chen C, Kong P, Yu F, Lv Q, Wang Z, et al. Non‐Membrane Active Peptide Resensitizes MRSA to β ‐Lactam Antibiotics and Inhibits S. aureus Virulence. Advanced Science. 2025. doi:10.1002/advs.202416260
BibTeX
@article{Shi2025,
author = {Shi, Jingru and Chen, Chen and Kong, Pan and Yu, Feiyu and Lv, Qingyan and Wang, Zhiqiang and Liu, Yuan},
title = {Non‐Membrane Active Peptide Resensitizes MRSA to β ‐Lactam Antibiotics and Inhibits S. aureus Virulence},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202416260}
}
EUVIMED